Translational Medicine and Therapeutics Working Group

December 7, 2010

Arthur Rubenstein, M.B.B.Ch.
Executive Vice President, University of Pennsylvania for Health System and Dean, University of Pennsylvania School of Medicine
<table>
<thead>
<tr>
<th>Non-Federal</th>
<th>Federal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthur Rubenstein, MBBCh <strong>(Chair)</strong></td>
<td>Josephine Briggs, MD</td>
</tr>
<tr>
<td>William Brody, MD, PhD</td>
<td>Anthony Fauci, MD</td>
</tr>
<tr>
<td>Gail Cassell, PhD</td>
<td>Eric Green, MD, PhD</td>
</tr>
<tr>
<td>William Roper MD, MPH</td>
<td>Stephen Katz, MD, PhD</td>
</tr>
<tr>
<td>Solomon Snyder, MD</td>
<td>Griffin Rodgers, MD, MACP</td>
</tr>
<tr>
<td>Huda Zoghbi, MD</td>
<td>Susan B. Shurin, MD</td>
</tr>
<tr>
<td>Norman Augustine <strong>(ad hoc)</strong></td>
<td>Harold Varmus, MD</td>
</tr>
<tr>
<td></td>
<td>Francis Collins, MD, PhD <strong>(ex officio)</strong></td>
</tr>
</tbody>
</table>
Presentation Overview

• Impetus for Deliberations and TMAT Charge
• Deliberative Process
• Working Group Findings
• Working Group Recommendations
Despite greater investments in R&D by pharma, FDA approvals of new medical entities have declined.

- Pharmaceutical Research and Manufacturers of America; FDA
Impetus for Deliberations: Prior Recommendations

“...the Committee sees a critical lack of coordination and standardization across NIH in its clinical research programs that cause many opportunities for collaboration and data sharing across fields to be lost.”

- From the National Research Council and Institute of Medicine report titled *Enhancing the Vitality of the National Institutes of Health: Organizational Change to Meet New Challenges* (2003)
Impetus for Deliberations: NIH Director’s Opportunities

• Applying high throughput technologies to understand fundamental biology, and to uncover the causes of specific diseases

• Translating basic science discoveries into new and better treatment

• Putting science to work for the benefit of health care reform

• Encouraging a greater focus on global health

• Reinvigorating and empowering the biomedical research community

Working Group Charge

• Identify the attributes, activities, and functional capabilities of an effective translational medicine program for advancing therapeutics development

• Broadly assess, from a high-level view, the NIH landscape for extant programs, networks, and centers for inclusion in this program and recommend their optimal organization

• In addressing its charge, the Working Group will consider how the Agency could leverage and organize a wide range of existing NIH resources and effectively implement the Cures Acceleration Network (CAN) (assuming appropriation of funds)
Working Group Considerations

• Additionally, in executing its charge, the TMAT Working Group should consider the following:
  – Current NIH-supported infrastructure, initiatives, and resources with direct relevance to the therapeutics development pipeline;
  – Methods to synergize, and avoid competition with, resources in the private sector;
  – Prior recommendations for strengthening the clinical and translational research enterprise at NIH, including recommendations of the IOM, and relevant lessons learned from industry, academia, non-profit organizations, etc.; and
  – Metrics and methodologies that could be used for evaluating the impact of changes in the organization and management of the therapeutics development program.
Overview of TMAT Deliberative Process

- Apply framework and process for considering change, as outlined by the Deliberating Organizational Change and Effectiveness (DOCE) Working Group:
Is TMAT research at NIH capitalizing on scientific opportunities and/or meeting public health needs? Could reorganization better optimize TMAT research at NIH?

Step 1.
Assess the Need for Change

Step 2.
Evaluate Options for Change

Step 3.
Implement and Evaluate the Change

What are the options for organizational change? Which option would best optimize TMAT research at NIH?

How should the change be implemented and navigated? How should the effectiveness of the change be evaluated?
Since May 2010, the Working Group has held 5 teleconferences and 1 two-day stakeholder consultation, hearing from diverse groups and sectors, including:

- Patient advocacy groups
- Leaders of academic health centers
- Clinical and Translational Science Awards recipients
- Venture capitalists
- Industry specialists
- Non-profit organizations
- NIH institute and center staff
- Councils of NCRR and CC
Working Group Findings: Assessing the Need for Change

- **EMERGING SCIENTIFIC OPPORTUNITIES**
  - Scientific discoveries have generated a large inventory of potential targets for new products
  - Rapid advances in innovative technology have made processes more efficient and affordable
  - Interest and expertise in therapeutics development are growing at academic institutions

- **EVOLVING LANDSCAPE OF THERAPEUTICS DEVELOPMENT**
  - Efforts by biotech and pharmaceutical companies have slowed due to lack of available venture capital and shrinking resources for R&D
  - A shift from a siloed approach towards one that is more integrated and modular is needed, capitalizing upon the respective strengths of the government and the private sector
• **SYNERGY IN LEVERAGING RESOURCES EFFECTIVELY**
  – Extant and emerging programs at NIH are increasingly well equipped to catalyze progress in therapeutics development
  – NIH possesses scientific and technological resources that can enable unique partnerships with diverse organizations, entities, sectors, etc.

• **AUTHORIZATION OF CURES ACCELERATION NETWORK**
  – Both Congress and the American public look to NIH to play a catalytic role in delivering on the promise of translational medicine, as reflected in the recent passage of the Patient Protection and Affordable Care Act (PL 111-148)
  – Legislation calls on NIH to establish a Cures Acceleration Network (CAN) to advance the development of “high need cures”
At the September 14-15, 2010 stakeholder consultation, participants identified the additional areas of opportunity:

- Developing and enhancing appropriate collaborations
- Training and supporting TMAT career paths
- Communicating a clear mission
Working Group Findings: Assessing the Need for Change (cont.)

Step 1.
Assess the Need for Change

| Is TMAT research at NIH capitalizing on scientific opportunities and/or meeting public health needs? |
| Could reorganization better optimize TMAT research at NIH? |

**CONCLUSION OF THE TMAT WORKING GROUP**

The current NIH structure related to TMAT should be reorganized to capitalize best upon emerging scientific opportunities, adapt to and help shape the evolving landscape, create a home for the recently authorized CAN, and leverage existing NIH resources to speed the delivery of new, more effective medical products to patients.
Working Group Findings: Goals and Objectives of Reorganization

• **GOAL:** To expand and augment the agency’s efforts in advancing translational medicine and developing new therapeutics* and diagnostics

• Toward this end, it will be critical that NIH pursue a deliberate and rational approach that effectively:
  – Leverages existing efforts
  – Supports promising areas of research
  – Enhances synergy between public and private sectors

*Includes, but not limited to, drugs, biologics, and devices
FUNCTION: Support and strengthen TMAT research

ACTIVITIES:

– Develop and provide scientific resources (e.g., chemical libraries, high-throughput screening, repositories, unique research facilities) and expertise

– Enhance therapeutics development efforts within and across NIH
  • Provide services and expertise to NIH ICs
  • Augment the strengths and experience of IC-based activities
  • Inform the development of trans-NIH strategies
  • Incentivize research in areas of little interest in the private sector

– Streamline and improve the therapeutics development process
  • Facilitate effective transition between steps
  • Learn from successes and failures of each product
  • Design innovative approaches to product development

– Identify and bridge gaps
FUNCTION: Provide central locus for information on and access to resources, tools, and expertise related to TMAT

ACTIVITIES:

- Establish a visible home at NIH
  - Cluster and leverage core resources
  - Establish strong functional connections with relevant components of NIH
  - Publicize existing and new TMAT-related resources and activities at NIH

- Offer expertise and advice on advancing concepts from discovery to translation and assist efforts to navigate the therapeutics development process

- Develop resources for assisting in navigating regulatory pathways

- Develop and support data-sharing infrastructure

- Maintain knowledge of applicable resources, technology, programs, experts, partners, etc., at each phase of product development
FUNCTION: Serve as catalyst and convener for collaborative TMAT interactions and partnerships

ACTIVITIES:

- Facilitate and participate in partnerships, including identifying and matching potential partners
- Use convening power to promote mutual understanding of the cultures and goals of key sectors
- Facilitate effective hand-off of products to industry for further development and commercialization
- Establish mechanisms for navigating IP and COI concerns
- Incentivize sharing of abandoned products and the exploration of rescuing and repurposing products
Working Group Findings: Functional Capabilities and Activities (cont.)

**FUNCTION:** Expand the pre-competitive space

**ACTIVITIES:**

- Incentivize the publication of research failures and lessons learned
- Develop and incentivize use of informatics infrastructure for validation, curation, integration, and sharing pre-clinical data across sectors and distributing risk
- Engage in partnerships to conduct and support research in pre-competitive areas (e.g., advance disease understanding, biomarkers, disease models)
**FUNCTION:** Support training for translational research investigators

**ACTIVITIES:**

- Develop clear career tracks for TMAT research (including clinical pharmacology)
- Offer training grants for translational research education; including bioinformatics, systems biology, biomarker development, and cross-sector training (including FDA and pharma)
- Establish curriculum in regulatory science
**FUNCTION:** Enhance communication with and among all stakeholders regarding TMAT

**ACTIVITIES:**

- Identify opportunities to encourage NIH grantees to pursue the translation of their discoveries
- Foster greater communication and collaboration with other government agencies
- Increase outreach to the public, patient advocacy groups, Congress, and others
Step 1. Assess the Need for Change

Is TMAT research at NIH capitalizing on scientific opportunities and/or meeting public health needs?
Could reorganization better optimize TMAT research at NIH?

Step 2. Evaluate Options for Change

What are the options for organizational change?
Which option would best optimize TMAT research at NIH?

Step 3. Implement and Evaluate the Change

How should the change be implemented and navigated?
How should the effectiveness of the change be evaluated?
Working Group Findings: Relevant Extant NIH Resources for Consideration

- Molecular Libraries Program (MLP)
- Therapeutics for Rare and Neglected Diseases (TRND) Program
- NIH Rapid Access to Interventional Development (RAID) Program
- NIH-FDA Regulatory Science Initiative
- Clinical and Translational Science Awards (CTSAs)
- NIH Clinical Center (CC)
Working Group Findings: Potential Options for Organization

**Option 1: Structural unification of relevant components**

- Disease
- Target ID
- Assay Dev.
- HTS
- Hit to Lead
- Lead Optimization
- Pre-Clinical
- Ph. I
- Ph. II
- Ph. III
- Ph. IV

**Potential variants of Option 2**

- Include strong functional ties to the CTSAs (Option 2b); or
- Strong functional ties to the Clinical Center (Option 2c)

**Option 2a: Structural and functional unification of relevant components**
Working Group Recommendations

• It is proposed that NIH establish a new Center to:
  
  – *Develop and provide research infrastructure* for advancing translational medicine and therapeutics development
  
  – *Foster new and innovative strategies for TMAT research* by advancing a process engineering approach to developing therapeutics, including strengthening and streamlining the process itself
  
  – *Serve as a catalyst, resource, and convener for collaborative TMAT interactions and partnerships*, capitalizing on the relative strengths of the extra- and intramural communities, private sector, government, and academia, to promote quick-win, fast-fail paradigms and further develop the pre-competitive space
Working Group Recommendations: Organization of New Center

Strong functional ties to the Clinical Center (Option 2c)
Working Group Recommendations: Rationale for Organizational Structure

- Components of the core structure support activities, provide expertise, and enable access to resources (e.g., technologies) broadly applicable to a range of diseases

- CTSAs share a common vision for reducing the time it takes for laboratory discoveries to become treatments for patients, engaging communities in clinical research efforts, and training clinical and translational researchers—this consortium provides an existing national infrastructure for the conduct of translational research and is to be an essential component of the new Center

- The Clinical Center is a valuable resource and essential component of both the NIH Intramural Research Program and NIH’s translational medicine portfolio and subsequently should have a strong functional connection to a new Center devoted to TMAT research, but should not be structurally encompassed within the entity
Working Group Recommendations:
IRP Working Group Recommendations on CC

- At the SMRB meeting on September 14-15, 2010, members agreed to table the vote on IRP Working Group recommendations regarding the Clinical Center until the TMAT recommendations were finalized.

- Members of the TMAT Working Group continue to support the IRP Working Group’s recommendations regarding the vision and role, governance, and funding of the Clinical Center.

- The TMAT Working Group finds that the IRP Working Group’s recommendations regarding the Clinical Center are compatible with emerging TMAT recommendations.

- The TMAT Working Group anticipates synergy between the proposed Center and the recommended vision and role for the Clinical Center as a national resource.
Working Group Recommendations: Functions and Activities

• Bulk of the new Center’s activities should focus on providing and supporting resources, training, and tools to enable TMAT research

• As necessary, the new Center should house targeted activities to perform its functions (e.g., implement the Cures Acceleration Network)

• Functions and activities of any new Center should not duplicate, consume, or undermine the successful activities already underway within the NIH ICs
Specifically, the new Center should:

- Support and strengthen research in translational medicine and therapeutics development;
- Provide a central locus for information on and access to resources, tools, and expertise related to TMAT;
- Serve as a catalyst and convener for collaborative TMAT interactions and partnerships;
- Expand the pre-competitive space;
- Support training for TMAT investigators; and
- Enhance communication with and among all stakeholders.
Working Group Recommendations: Attributes

- Promotes collaboration across sectors
- Streamlines and accelerates the translation of basic research
- Provides a visible home for resources and expertise
- Employs metrics, benchmarks, timelines, and milestones in planning, management, and decision-making
- Promotes and allows flexibility in decision-making and priority-setting
- Facilitates culture shifts, including in cross-sector collaborations and internal peer review processes
Working Group Recommendations: Implementation and Evaluation

Step 3.
Implement and Evaluate the Change

- Successful implementation will require strong leadership, clearly delineated tasks, and cooperation from affected parties.
- The new Center should be evaluated periodically to determine whether it is meeting its goals and address any untoward consequences.
Working Group Recommendations: Metrics for Evaluation

• **Long-Term Metrics:** Evidence that the new Center has made contributions to the development of new products (including the pace of their discovery)

• **Interim Metrics:** Given the lengthy timelines, high-risk nature, and difficulty associated with TMAT research, interim metrics will be critical to enabling short-term evaluation and making necessary adjustments. Metrics should include:
  – Evidence of a portfolio that enhances the breadth and depth of Agency’s TMAT portfolio by complementing (and not duplicating or infringing on) successful IC initiatives
  – Evidence of increasing interdisciplinary and cross-sector research collaborations
  – Identification and support of new approaches and technologies enabling TMAT research
  – Evidence of increasing number of investigators participating in TMAT research
  – Evidence that TMAT efforts reveal new pathways and areas for basic discovery
  – Development and utilization of a TMAT-relevant web portal for internal and external stakeholder access
The Working Group noted that NCRR also possesses programs for establishing clinical research infrastructure, developing versatile new technologies and methods, providing access to state-of-the-art technologies and instruments, and developing and providing access to critical animal models—many of which have significant collaborations and interactions with the CTSAs across the country.

Given that many of NCRR’s resources are germane to the resource function of the proposed Center, the agency may choose to consider the incorporation of these relevant components.
Working Group Recommendations: Additional Considerations (cont.)

- Once the appropriate infrastructure has been established, NIH can determine what additional resources are needed to enhance rapid translation of basic discoveries into cures.

- In establishing the new Center, it will be critical for NIH to analyze previous experience in implementing translational medicine and therapeutics development programs, including lessons learned from both successes and failures.
Conclusions

• NIH could enhance its efforts in translating basic discoveries into new diagnostics and treatments by establishing a focused, integrated pipeline for therapeutics development.

• The mission of the new Center should complement the NIH’s mission of advancing fundamental biomedical research and improving human health—it should not detract from the agency’s emphasis on fundamental knowledge, but rather, stimulate the pursuit of new avenues of scientific inquiry.

• Formation of this new Center should not be delayed in the absence of a CAN appropriation.
Working Group Recommendation: Creation of a New Center

NIH should establish a new Center devoted to advancing translational medicine and accelerating therapeutics development.

The new Center should incorporate MLP, TRND, RAID, CTSAs, CAN, NIH-FDA Partnerships, and other existing components or new resources to be developed (as appropriate).